KNOXVILLE, Tenn., June 20 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals announced today that Provectus’ CEO Craig Dees, Ph.D., is scheduled to speak at the Annual Meeting of the American Society for Photobiology at 1:10 pm EDT on July 11 at the Westin Rio Mar in Rio Grande, Puerto Rico. Dees will present evidence that the active agent in the Company’s topical drug Xantryl(TM) may have utility in treating infections caused by highly dangerous antibiotic resistant bacteria. Xantryl is currently in clinical trials for the topical treatment of psoriasis.
Extremely dangerous bacteria like methicillin-resistant Staphyloccocci and vancomycin-resistant Enterococci are an ever-increasing health risk and pose severe challenges when treating human and animal infections. Evidence will be presented that diluted formulations of Xantryl can reproducibly kill large numbers of these bacteria upon several minutes illumination using light from standard fluorescent light bulbs.
“We are extremely pleased to show that Xantryl will kill the vast majority of these dangerous bacteria within just a few minutes,” stated Dees. “We’re also pleased that it requires only a simple light source that mimics exposure to ambient light. These findings potentially open important new markets in treating infectious disease with Xantryl.”
About Provectus Pharmaceuticals, Inc.:
Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of breast cancer, liver cancer, and metastatic melanoma. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company’s topical agent Xantryl(TM), a treatment for psoriasis.
The Company’s offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865-769-4011. For more information, contact the Company at info@pvct.com or visit the corporate Web site: http://www.pvct.com .
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward-looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.
Provectus Pharmaceuticals, Inc.
CONTACT: Investors, Matt Clawson of Allen & Caron Inc., for ProvectusPharmaceuticals, Inc., +1-949-474-4300, matt@allencaron.com; PeterCulpepper of Provectus Pharmaceuticals, Inc., +1-865-769-4011,culpepper@pvct.com
Web site: http://www.pvct.com/
